Sandoz announces plans to further strengthen its antibiotics manufacturing setup in Europe
May 18, 2021 04:45 ET
|
Novartis Pharma AG
Sandoz to invest €150 million in new antibiotics manufacturing technology in Europe over next three to five years, to be optimally prepared for future needsKundl, Austria further strengthens...
Wichtige Wachstumstreiber und Neueinführungen von Novartis setzen ihre Dynamik im ersten Quartal fort und erhalten das Vertrauen in das Wachstum; Konzernprognose für 2021 bestätigt
April 27, 2021 01:00 ET
|
Novartis Pharma AG
Der Nettoumsatz sank im ersten Quartal um –2% (kWk¹, +1% USD) infolge der COVID-19-bedingten Vorratskäufe im Vorjahr (rund USD 0,4 Milliarden) Die Geschäftseinheit Pharmaceuticals blieb auf...
Novartis: moteurs clés de la croissance et lancements poursuivent leur essor au 1er trimestre, maintenant la confiance dans la croissance. Confirmation des prévisions pour le Groupe pour 2021
April 27, 2021 01:00 ET
|
Novartis Pharma AG
Chiffre d’affaires net du T1 en recul de -2% (tcc¹, +1% USD), impacté par les achats anticipés au T1 2020 en lien avec le Covid-19 (env. USD 0,4 milliard) Pharmaceuticals: le chiffre d’affaires net de...
Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.
April 27, 2021 01:00 ET
|
Novartis Pharma AG
Q1 net sales declined -2% (cc¹, +1% USD), due to prior year COVID-19 related forward purchasing (approximately USD 0.4 billion) Pharmaceuticals BU in line with prior year (0% cc, +4% USD) with...
Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)
March 30, 2021 01:15 ET
|
Novartis Pharma AG
Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74Broad...
Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
March 23, 2021 02:15 ET
|
Novartis Pharma AG
Phase III VISION study with 177Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive...
Novartis appoints Karen Hale as Chief Legal Officer
March 22, 2021 02:00 ET
|
Novartis Pharma AG
Basel, March 22, 2021 — Novartis announced today the appointment of Karen L. Hale as Chief Legal Officer. She will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive...
New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment
March 15, 2021 06:00 ET
|
Novartis Pharma AG
Children with SMA treated presymptomatically achieved age-appropriate motor milestones including sitting, standing and walking; required no ventilatory or feeding tube support; and had no serious,...
Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer
March 09, 2021 01:00 ET
|
Novartis Pharma AG
Phase III CANOPY-2 trial did not meet primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer whose cancer progressed...
Novartis announces change to the Executive Committee
March 05, 2021 01:00 ET
|
Novartis Pharma AG
Shannon Klinger, Chief Legal Officer, to leave Novartis on March 15, 2021Thomas Kendris appointed Chief Legal Officer ad interimBasel, March 5, 2021 — Novartis announced today that Shannon Thyme...